Ehsan Malek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ehsan Malek has a total of 280 co-authors. Here are the top co-authors by number of shared publications:
- James Joseph Driscoll
Division of Hematology & Oncology, Case Western Reserve University, Cleveland, OH USA
105 shared publications - Drew Adams
Case Western Reserve University School of Medicine
99 shared publications - James J. Ignatz-Hoover
Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio
99 shared publications - Priyanka Shailendra Rana
Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio
99 shared publications - Yuriy Federov
Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, USA
99 shared publications - Byung-Gyu Kim
Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio
73 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 195
Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study
- 2 November 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 195
Open AccessDenosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Figure S9. Effect of Btz and Compound A alone and combined in a. RPMI-8226, b. ARH77, c. U266 and d. E.G7-Ova cells. Cell viability was determined using the XTT assay. Assays were performed in triplicate. Staurosporine (ST, 2 uM) represents a positive control for cell death.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Figure S9. Effect of Btz and Compound A alone and combined in a. RPMI-8226, b. ARH77, c. U266 and d. E.G7-Ova cells. Cell viability was determined using the XTT assay. Assays were performed in triplicate. Staurosporine (ST, 2 uM) represents a positive control for cell death.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 7 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
CD86 expression on patient MM cells prior to CAR T therapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 7 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
CD86 expression on patient MM cells prior to CAR T therapy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 3 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of CAR T cell mitochondrial metabolism.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 3 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of CAR T cell mitochondrial metabolism.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Figure S6. Effect of Compound A on the viability of ARH77 and U266 cells alone or combined with ICIs and CD8+ T-cells. Similar to as shown in Fig. 7f, MM and CD8+ T-cells were separately treated with or without Compound A and the indicated agents (BTZ, TGFβ, ICIs). Following co-culture, the relative percent of viable MM cells was quantitated by annexin-V and propidium iodide staining and flow cytometry. Assays were performed in triplicate.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Figure S6. Effect of Compound A on the viability of ARH77 and U266 cells alone or combined with ICIs and CD8+ T-cells. Similar to as shown in Fig. 7f, MM and CD8+ T-cells were separately treated with or without Compound A and the indicated agents (BTZ, TGFβ, ICIs). Following co-culture, the relative percent of viable MM cells was quantitated by annexin-V and propidium iodide staining and flow cytometry. Assays were performed in triplicate.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Figure S7. Effect of Compound A pretreatment in vitro on the growth of E.G7-Ova-GFP-Luc tumors in vivo. a. Schematic representation of the experimental details with a timeline of treatments and tumor measurements. b. Phase contrast and FITC images of E.G7-Ova and E.G7-Ova-GFP-Luc cells. Scale bar = 100µm c. Relative luciferase activity in E.G7-Ova and E.G7-Ova-GFP-Luc cells. d. TBW for individual mice treated with either vehicle or Compound A. e. Average total flux as a measure of tumor burden in mice injected with vehicle or Compound A pretreated E.G7-Ova-Luc-GFP cells. Tumor burden (y-axis) was quantified as total flux (p/s) and monitored post-implantation (x-axis). Total flux represents a measure of the radiance (photons/sec) in each pixel integrated over the ROI area (cm2) x 4π. Average radiance was calculated by summing the radiance from each pixel within the ROI and then dividing by the number of pixels, resulting in units of photons/second/cm²/steradian. f. BLI of E.G7-Ova-GFP-Luc tumors from vehicle and Compound A-treated cells. Negative control represents an OT-1 mouse that was not injected with E.G7-Ova-GFP-Luc cells nor treated. Scale bar = 2 cm g. Percent survival of mice following injection of E.G7-Ova-GFP-Luc cells pretreated with either vehicle or Compound A.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Figure S7. Effect of Compound A pretreatment in vitro on the growth of E.G7-Ova-GFP-Luc tumors in vivo. a. Schematic representation of the experimental details with a timeline of treatments and tumor measurements. b. Phase contrast and FITC images of E.G7-Ova and E.G7-Ova-GFP-Luc cells. Scale bar = 100µm c. Relative luciferase activity in E.G7-Ova and E.G7-Ova-GFP-Luc cells. d. TBW for individual mice treated with either vehicle or Compound A. e. Average total flux as a measure of tumor burden in mice injected with vehicle or Compound A pretreated E.G7-Ova-Luc-GFP cells. Tumor burden (y-axis) was quantified as total flux (p/s) and monitored post-implantation (x-axis). Total flux represents a measure of the radiance (photons/sec) in each pixel integrated over the ROI area (cm2) x 4π. Average radiance was calculated by summing the radiance from each pixel within the ROI and then dividing by the number of pixels, resulting in units of photons/second/cm²/steradian. f. BLI of E.G7-Ova-GFP-Luc tumors from vehicle and Compound A-treated cells. Negative control represents an OT-1 mouse that was not injected with E.G7-Ova-GFP-Luc cells nor treated. Scale bar = 2 cm g. Percent survival of mice following injection of E.G7-Ova-GFP-Luc cells pretreated with either vehicle or Compound A.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Figure S5. Effect of Compound A on pan-MHC-I expression. a. ARH77 and U266 cells were treated with Compound A and probed with pan-MHC-I or MHC-I subtype allele-specific antibodies after which the samples were analyzed by flow cytometry. Pretreatment with Compound A significantly increased pan-MHC class-I HLA-ABC and HLA-B surface presentation in all MMCLs assayed. b. ARH77 and U266 cells were pre-treated with Compound A for 48 h after which they were washed and co-cultured with healthy CD8+ cytotoxic T-cells for 18 h at the E:T ratios of 1:1, 2:1and 3:1. Compound A increased CTL-mediated cytotoxicity of tumor cells which was measured by gating for CD138, Annexin-V and PI positive cells at E:T 2:1 and 3:1. Pretreatment of MMCLs and T-cells alone with Compound A resulted in ∼5-10% cell death which was enhanced further when MM cells were co-cultured at E:T ratios of 2:1 and 3:1. T-cells alone also did not show significant cell death when pre-treated with Compound A. There was <5% MM cell death detected with or without Compound A treatment. Similar results were observed with CD8+ T-cells alone. c. Effect of Compound A on the viability of ARH77 and U266 cells alone or combined with ICIs and CD8+ T-cells. MM cells and CD8+ T-cells were separately treated with or without Compound A and the indicated agents. Following co-culture, the relative percent of indicated viable cells was quantitated by annexin-V and propidium iodide staining and flow cytometry. c. Effect of Compound A on T-cell exhaustion markers. CD8+ T-cells were treated with compound A for 24 h after which they were assessed for surface expression of PD-1, TIM-3, CTLA-4, and LAG-3. Compound A induced a marked decrease in PD-1 surface expression, while no significant change was observed in TIM-3, CTLA-4, and LAG-3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Figure S5. Effect of Compound A on pan-MHC-I expression. a. ARH77 and U266 cells were treated with Compound A and probed with pan-MHC-I or MHC-I subtype allele-specific antibodies after which the samples were analyzed by flow cytometry. Pretreatment with Compound A significantly increased pan-MHC class-I HLA-ABC and HLA-B surface presentation in all MMCLs assayed. b. ARH77 and U266 cells were pre-treated with Compound A for 48 h after which they were washed and co-cultured with healthy CD8+ cytotoxic T-cells for 18 h at the E:T ratios of 1:1, 2:1and 3:1. Compound A increased CTL-mediated cytotoxicity of tumor cells which was measured by gating for CD138, Annexin-V and PI positive cells at E:T 2:1 and 3:1. Pretreatment of MMCLs and T-cells alone with Compound A resulted in ∼5-10% cell death which was enhanced further when MM cells were co-cultured at E:T ratios of 2:1 and 3:1. T-cells alone also did not show significant cell death when pre-treated with Compound A. There was <5% MM cell death detected with or without Compound A treatment. Similar results were observed with CD8+ T-cells alone. c. Effect of Compound A on the viability of ARH77 and U266 cells alone or combined with ICIs and CD8+ T-cells. MM cells and CD8+ T-cells were separately treated with or without Compound A and the indicated agents. Following co-culture, the relative percent of indicated viable cells was quantitated by annexin-V and propidium iodide staining and flow cytometry. c. Effect of Compound A on T-cell exhaustion markers. CD8+ T-cells were treated with compound A for 24 h after which they were assessed for surface expression of PD-1, TIM-3, CTLA-4, and LAG-3. Compound A induced a marked decrease in PD-1 surface expression, while no significant change was observed in TIM-3, CTLA-4, and LAG-3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Figure S1. Chemical structure of the eight hits, designated as Compounds A-H, detected in the high throughput screen. Also shown are the known HDAC6 inhibitors tubastatin-A, ACY-1215, ACY-738, and nexturastat A.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Figure S1. Chemical structure of the eight hits, designated as Compounds A-H, detected in the high throughput screen. Also shown are the known HDAC6 inhibitors tubastatin-A, ACY-1215, ACY-738, and nexturastat A.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Figure S4. Effect of Compound A on murine H2Kb MHC-I-SIINFEKL presentation and B3Z tumor lysis. a. Effect of the eight hits on proteasomal ChT-like activity at increasing concentrations in E.G7-ova cells. Compounds that increased proteasome ChT-like activity >1.5-fold and maintained cell viability >50% are represented by red boxes. b. Effect of the eight hits on proteasomal ChT-like activity and SIINFEKL-MHC-I complex presentation in E.G7-ova cells. E.G7-Ova cells were pre-treated with the indicated compounds for 72 h after which they were stained with a monoclonal antibody to SIINFEKL-bound to H2Kb. Fluorescence was quantitated by flow cytometry. Red boxes indicate compounds that increased proteasomal activity >1.5-fold, and increased SIINFEKL-H2Kb presentation >2-fold. c. Effect of the eight hits that increased proteasomal ChT-like activity with SIINFEKL-MHC-I complex presentation on lysis of E.G7-Ova cells by the B3Z T-cells. E.G7-Ova cells were pretreated with compounds (1 uM) after which cells were washed and co-cultured with the H-2Kb-restricted B3Z T-cells genetically engineered to express a TCR that specifically recognizes the SIINFEKL-H2Kb complex. E.G7-Ova cells were co-cultured with B3Z cells at E:T ratios of 1:1, 2:1, and 3:1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity
Figure S4. Effect of Compound A on murine H2Kb MHC-I-SIINFEKL presentation and B3Z tumor lysis. a. Effect of the eight hits on proteasomal ChT-like activity at increasing concentrations in E.G7-ova cells. Compounds that increased proteasome ChT-like activity >1.5-fold and maintained cell viability >50% are represented by red boxes. b. Effect of the eight hits on proteasomal ChT-like activity and SIINFEKL-MHC-I complex presentation in E.G7-ova cells. E.G7-Ova cells were pre-treated with the indicated compounds for 72 h after which they were stained with a monoclonal antibody to SIINFEKL-bound to H2Kb. Fluorescence was quantitated by flow cytometry. Red boxes indicate compounds that increased proteasomal activity >1.5-fold, and increased SIINFEKL-H2Kb presentation >2-fold. c. Effect of the eight hits that increased proteasomal ChT-like activity with SIINFEKL-MHC-I complex presentation on lysis of E.G7-Ova cells by the B3Z T-cells. E.G7-Ova cells were pretreated with compounds (1 uM) after which cells were washed and co-cultured with the H-2Kb-restricted B3Z T-cells genetically engineered to express a TCR that specifically recognizes the SIINFEKL-H2Kb complex. E.G7-Ova cells were co-cultured with B3Z cells at E:T ratios of 1:1, 2:1, and 3:1.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessKey Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models